AVBP | ArriVent BioPharma, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	23.67 - 24.61
52 Week Range	14.35 - 30.99
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	147,132
Average Volume	156,839
Shares Outstanding	33,585,890
Market Cap	826,548,753
Sector	Healthcare
Industry	Biotechnology
IPO Date	2024-01-26

Valuation
Profitability
Growth
Health
P/E Ratio	-11.04
Forward P/E Ratio	N/A
EPS	-2.23
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	40
Country	USA
Website	AVBP

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

*Chart delayed

Analyzing fundamentals for AVBP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see AVBP Fundamentals page.

Watching at AVBP technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on AVBP Technicals page.